Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
July 17, 2026

Telehealth 2.0: Is Amwell Quietly Becoming The Operating System Of Hybrid Care? -( $AMWL )

Amwell, Inc. (NYSE: AMWL, $13,02, +165.07% YTD)) is quietly scripting one of Wall Street’s more intriguing digital‑health turnarounds—an AI‑infused, platform‑first story backed by a management bench that looks more like a health‑tech all‑star team than a typical telehealth cast.

Digital Care, Rewritten

American Well Corporation, better known as Amwell, operates a SaaS‑based digital care enablement platform that connects payers, health systems and virtual care programs across the U.S. and internationally. The company’s Converge platform was designed as an open, cloud‑native architecture that integrates wearables, remote monitoring, AI tools and electronic health records into a unified, virtual front door for care. In essence, Amwell is angling to be the operating system of hybrid care—where in‑person visits, virtual appointments, remote monitoring and asynchronous workflows live inside one coordinated, data‑rich environment. That ambition positions AMWL squarely at the intersection of healthcare technology, AI‑powered workflows and payer/provider cost containment, themes that increasingly resonate with institutional and retail investors alike.

The Market’s Second Opinion On AMWL

Shares of Amwell (AMWL) have been volatile but show signs of renewed investor interest, with the stock recently trading in a range just above 13 dollars and sporting a 52‑week span that has stretched from the low single digits to the low double digits. The price trajectory reflects a broader re‑rating of digital health after the post‑pandemic hangover, with Amwell’s year‑to‑date performance outpacing the S&P 500 as investors reassess software‑driven recurring revenue versus legacy visit‑based economics. Analyst commentary has largely centered on the company’s path to profitability, with emphasis on operating losses, revenue guidance tied to the Converge replatforming, and the need for scale benefits to show up in margins. Yet, earnings call commentary has highlighted software revenue growth and a targeted improvement in adjusted EBITDA, suggesting that AMWL is deliberately trading near‑term profitability for strategic positioning in a market that is still in the early innings of virtual‑first care adoption.

The Schoenberg Blueprint: From ICU Software To Global Virtual Care

At the center of Amwell’s narrative is co‑founder and Chairman & CEO Ido Schoenberg, M.D., who has been steering the company since 2006 and is widely viewed as one of the pioneers of virtual healthcare. Before launching Amwell, Schoenberg co‑founded iMDSoft, which built enterprise software to automate hospital critical care units across the U.S., Europe and East Asia, giving him a deep appreciation for real‑world clinical workflows and high‑acuity environments. Schoenberg later served as CEO of CareKey Inc., guiding it through an acquisition by TriZetto, where he became Chief Business Strategy Officer—a role that blended payer economics, technology and healthcare operations. That background matters to investors: it suggests that Amwell’s strategic direction is shaped by someone who has repeatedly scaled health‑tech companies, navigated complex hospital and payer landscapes, and understands that digital health must ultimately earn its keep on the P&L, not just the conference circuit.

Global Reach, Diamond Hands: Phyllis Gotlib

If Amwell’s international ambitions feel unusually credible for a mid‑cap health‑tech name, it may be because they are led by Phyllis Gotlib, President, Amwell International. Gotlib previously co‑founded and served as CEO of iMDSoft, where she guided the company from inception through rapid international expansion and its eventual acquisition by TPG Growth, demonstrating a knack for scaling complex hospital technology across borders. Her experience spans clinical information systems, boutique investment work at Tactic Capital Markets, and active roles in healthcare‑focused venture activity, including work with Flare Capital. For investors, that mix of operator, investor and international strategist suggests Amwell’s global playbook is in the hands of an executive who has already graduated from the school of cross‑border healthcare integration—no extra tuition required.

The Numbers Guy Who’s Seen This Movie Before: Mark Hirschhorn

Mark Hirschhorn, Amwell’s Chief Financial Officer and Chief Operating Officer, brings more than three decades of financial and strategic experience in healthcare technology, and importantly, a résumé that reads like a tour through the modern history of virtual care. Hirschhorn previously served in dual CFO/COO roles at Teladoc Health, where he helped grow the company and solidify virtual care as a recognized arm of healthcare delivery, and later held senior leadership roles at Talkspace. At Amwell, Hirschhorn oversees the company’s financial architecture, enterprise‑wide optimization and capital allocation, a critical mandate as the firm balances investment in growth with the need to demonstrate leverage and eventual profitability. His board role at NextCare, one of the largest urgent care providers in the U.S., adds brick‑and‑mortar insight to his virtual‑care experience—a combination that should be particularly interesting to investors focused on hybrid models where physical sites and digital platforms co‑create the margin story.

Clinical Gravity: Dr. Cynthia Horner And The Medical Engine

Any digital‑health platform is only as credible as the clinicians who trust it, and that’s where Chief Medical Officer Dr. Cynthia Horner enters the frame. Horner oversees thousands of clinicians delivering virtual care on Amwell’s platform worldwide and leads Amwell Medical Group (AMG) programs across virtual primary care, urgent care, women’s health and behavioral health, among other services. Her remit includes working with hospital systems, payers, and Amwell’s product and engineering teams to design clinical solutions that aim for high‑quality outcomes, reduced friction, and adherence to complex regulatory requirements—a trifecta that tends to determine whether digital care becomes an enterprise standard or a pilot project that disappears after the grant runs out. With two decades of family medicine experience and involvement in telehealth education via the American Board of Telehealth, Horner anchors Amwell’s strategy firmly in clinical reality, a point that institutional investors increasingly scrutinize in health‑tech diligence.

Revenue Engines And Relationships: Michael Miller’s Payer Playbook

On the commercial front, Senior Vice President and Chief Sales Officer Michael Miller leads Amwell’s sales strategy, with a primary focus on the payer market. Miller brings more than 34 years of healthcare experience, including senior roles at Evolent Health Services, TriZetto/Cognizant, HealthEdge, WebMD and GE Medical Systems—names that collectively map the evolution of payer platforms, benefit administration and health IT over the last three decades. For investors, the significance is straightforward: Amwell’s go‑to‑market is led by someone deeply familiar with how payers think about network design, medical cost containment and member experience, and how technology vendors must position to win multi‑year contracts in that environment. That expertise is particularly relevant as AMWL’s platform aims to make virtual care not just clinically viable but economically compelling for insurers and risk‑bearing entities

AI At The Core: Dan Zamansky’s Technology Mandate

The technical backbone of Amwell’s ambitions is overseen by Chief Product and Technology Officer Dan Zamansky, whose prior 11‑year tenure at Amazon included leadership in product management, engineering and cloud‑based AI. Zamansky founded and led AWS Health AI, Amazon’s initiative to democratize access to healthcare and life sciences AI via Amazon Web Services, and previously served as Head of Product for Amazon ElastiCache and General Manager of core platform services at Amazon Advertising. That background gives Amwell a leadership voice fluent in large‑scale cloud infrastructure, AI tooling and data‑intensive platform design—exactly the ingredients needed to transform telehealth from video visit scheduling into a continuously learning, workflow‑driven ecosystem. For investors who view AI as less a buzzword and more a necessary engine for automation, triage, documentation and personalization, Zamansky’s presence is a meaningful signal that AMWL’s product roadmap is being shaped by someone who has shipped real, scaled AI services in production.

Government Scale And Mission Alignment: Timothy Kleinsmith

In the public‑sector and federal space, Amwell’s Government Programs are led by Area Vice President Timothy Kleinsmith. Kleinsmith previously worked with the Department of Veterans Affairs as a Director and Senior Consultant at Echo Five Group and served 10 years in the U.S. Army, holding leadership roles up to Senior Enlisted Advisor to the Army Surgeon General. This mix of military healthcare, federal systems navigation and veteran advocacy is particularly relevant as government agencies increasingly adopt virtual and hybrid care models to reach geographically dispersed populations. Within Amwell, Kleinsmith’s leadership, including his work establishing a Veterans Employee Resource Group, suggests the company’s government strategy is not merely a business development line item but a mission‑aligned effort to integrate digital care into the fabric of federal health systems—an arena where winning a single multi‑year contract can rewrite a revenue trajectory.

Strategic Positioning: Why AMWL Belongs On Investor Screens

Viewed through an investor’s lens, Amwell offers a blend of characteristics that can be compelling for those comfortable with higher‑beta, execution‑sensitive stories in healthcare technology.

  • A founder‑led culture with deep health‑tech experience, giving AMWL a strategic continuity that many younger digital‑health names lack.
  • A platform‑first architecture (Converge) that aims to unify disparate digital health tools—AI, remote monitoring, second opinions, wearables—into one enterprise‑grade workflow environment.
  • A management team that collectively spans hospitals, payers, telehealth pioneers, cloud AI, government healthcare and international expansion, creating a diversified leadership risk profile uncommon in small‑ to mid‑cap health‑tech.

Naturally, AMWL is not a “set‑and‑forget” story: the company still faces the familiar challenges of converting innovation into scalable profitability, navigating reimbursement dynamics, and competing with larger players in virtual care and integrated delivery networks. But for investors searching for a digital‑health name where management depth, platform design and secular tailwinds rhyme, Amwell merits a deliberate look—perhaps one conducted, appropriately, via a virtual second opinion.

The Sources

Here’s a numbered list of the key sources used, with direct links:

  1. Amwell leadership team – “Meet Amwell’s Leadership Team – Visionaries in Digital Care”
    https://business.amwell.com/about-us/leadership-team
  2. Yahoo Finance – American Well Corporation (AMWL) Quote page
    https://finance.yahoo.com/quote/AMWL/
  3. StockTitan – American Well Corporation (AMWL) overview, price, news & analysis
    https://www.stocktitan.net/overview/AMWL/
  4. Robinhood – American Well (AMWL) stock price quote & news
    https://robinhood.com/us/en/stocks/AMWL/
  5. Morningstar – American Well Corp Ordinary Shares – Class A (AMWL) quote
    https://www.morningstar.com/stocks/xnys/amwl/quote
  6. Investing.com – American Well Corp (AMWL) stock price and news
    https://www.investing.com/equities/american-well-corp
  7. MarketScreener – American Well Corporation (AMWL:NYSE) stock quote, chart and analysis
    https://www.marketscreener.com/quote/stock/AMERICAN-WELL-CORPORATION-112492574/
  8. TradingView – AMWL stock price and live chart
    https://www.tradingview.com/symbols/NYSE-AMWL/
  9. The Motley Fool – American Well (NYSE: AMWL) stock price & news
    https://www.fool.com/quote/nyse/amwl/
  10. Seeking Alpha – AMWL American Well Corporation stock price & overview
    https://seekingalpha.com/symbol/AMWL
  11. Amwell – The Amwell Platform resources and digital care overview
    https://resources.amwell.com/the-amwell-platform-resources
  12. Fierce Healthcare – “Amwell rolls out new telehealth platform that integrates with digital health tools”
    https://www.fiercehealthcare.com/tech/amwell-rolls-out-new-telehealth-platform-integrates-wearables-ai-tools
July 17, 2026

When Ransomware Milks a Billion‑Dollar Brand: Coca‑Cola, fairlife and the New Cyber Risk Premium -( $KO )

Wall Street just got a reminder that in 2026, “moat” now means firewalls, backups, and incident response plans as much as pricing power and brand equity. In a week where dairy tanks went quiet and industrial control systems hummed nervously, the investing thesis is increasingly simple: cyber risk is now a core factor in cash flows, valuations, and national security.

When Ransomware Meets a Billion-Dollar Brand

The Coca-Cola Company (NYSE: KO) disclosed that its wholly owned dairy unit, fairlife, LLC, temporarily suspended U.S. production after a ransomware event led to unauthorized access to portions of its systems, including production-related systems. Product quality and safety reportedly remain intact, but U.S. operations are offline while Canada continues to churn out ultra-filtered milk as usual—an oddly modern version of “the plant across the border is fine.”In a filing, Coca-Cola acknowledged it has not yet determined whether the incident is “reasonably likely to materially affect” the company, a phrase that reads like legalese but should sound to investors like “watch this space for margin noise and working-capital friction.” Historically, ransomware events in food and beverage have translated into weeks-long production disruptions, logistics snarls, and the kind of empty shelves consumers notice—and analysts model.

Cyber Risk: From IT Line Item to Core Investment Theme

Huntress data suggests approximately 600 million cyberattacks occur worldwide each day, with 54% of surveyed U.S. organizations reporting a malware incident and 44% suffering phishing or spearphishing over a recent 12‑month period. Financial gain is the primary suspected motive, followed by data theft—ironically making corporate networks one of the most reliable “growth markets” in the world. The most common attack modalities—malware (including ransomware), phishing and social engineering, network‑level assaults such as DDoS, and credential‑based attacks like stuffing and spraying—now read like a standard risk factors list in SEC filings. For boards and CIOs, the pivot is clear: cyber defense has migrated from “insurance policy” status to capital allocation priority, influencing where incremental dollars go between capex, buybacks, and dividends.

Iran, Industrial Systems, and the New Geopolitical Beta

Federal advisories and media reporting point to Iran‑linked threat actors escalating cyber operations against U.S. critical infrastructure, with successful disruptions at multiple oil, gas, and water sites that in some cases forced facilities back to manual operations. These campaigns often target internet‑accessible programmable logic controllers and SCADA displays, the digital nerve centers that quietly keep water clean and energy flowing. U.S. agencies have warned that the objective is explicitly to generate “disruptive effects within the United States,” a description that should make any portfolio manager mentally translate “operational interruption” into “EPS volatility” and “higher risk premia for exposed sectors.” For investors, state‑linked cyber activity adds a new dimension of geopolitical beta, where exposure isn’t just to oil prices or sanctions but to the resilience—or fragility—of industrial software stacks.

The Investor Lens: Winners, Losers, and Pricing Cyber Resilience

For consumer staples names like KO, near‑term questions will focus on revenue impact from suspended fairlife production, cost inflation from remediation, and any acceleration in cyber‑capex and insurance spend. Longer term, the market will increasingly differentiate between companies that treat cyber as an operational discipline versus a PR exercise, rewarding those with visible investments in detection, response, backups, segmentation, and third‑party risk management. On the other side of the trade, cybersecurity vendors—especially those in managed endpoint detection and response (EDR), identity protection, industrial control security, and incident‑response services—are benefiting from a secular tailwind, as organizations scramble to address threats ranging from ransomware to AI‑powered phishing and deepfake social engineering. The fairlife incident is likely to be another slide in the boardroom deck that pushes budgets toward managed EDR, multi‑factor authentication, industrial network monitoring, and cyber insurance, all of which translate into multi‑year revenue visibility for sector leaders.

From “Black Swan” to Base Case: Positioning Portfolios

The Huntress taxonomy of 36 common attack types—from ransomware and infostealers to supply‑chain compromises and watering‑hole attacks—underscores that cyber incidents are no longer rare, idiosyncratic shocks but part of the base case operating environment. Most attacks still begin with a vulnerability: unpatched software, weak authentication, human error, or poor network segmentation, which means that cyber “alpha” for corporates is largely earned through mundane, repeatable best practices rather than shiny silver bullets.

For investors, practical portfolio implications include:

  • Favoring companies with transparent cyber governance, regular disclosure, and tested business continuity plans, especially in consumer staples, healthcare, financials, and industrials.
  • Treating repeat or opaque cyber incidents as a governance red flag that can justify valuation discounts or tighter risk limits.
  • Leaning into cybersecurity and infrastructure‑protection names as structural beneficiaries of both criminal and nation‑state activity, while remaining selective on valuation given intense competition and rapid technology cycles.

The fairlife ransomware episode won’t be the last time an everyday product vanishes from U.S. shelves because someone, somewhere, clicked the wrong link or left a system exposed. The investable takeaway is straightforward: in an era where Iran‑linked actors can nudge industrial sites offline and criminal groups can pause a billion‑dollar dairy brand, cyber resilience isn’t just an IT concern—it’s a core pillar of any credible investment narrative.

The Sources


[1] US warns of Iran-affiliated cyber-attacks on critical infrastructure across country https://www.theguardian.com/world/2026/apr/07/iran-cyberattacks-infrastructure
[2] Coca-Cola says fairlife halts US production after cyber attack https://www.reuters.com/business/coca-cola-says-fairlife-halts-us-production-after-cyber-attack-2026-07-16/
[3] Iran-linked hackers have disrupted multiple US industrial sites https://www.cnn.com/2026/04/07/politics/iran-linked-hackers-disrupt-us-industrial-sites
[4] Coca-Cola suspends U.S. production of billion-dollar brand after cyberattack https://www.ajc.com/business/2026/07/coca-cola-suspends-us-production-of-billion-dollar-brand-after-cyberattack/
[5] Coca-Cola suspended production at its Fairlife dairy after a ransomware attack https://finance.yahoo.com/technology/articles/coca-cola-suspended-production-fairlife-212231500.html
[6] The Coca-Cola Company Announces Technology Disruption … https://investors.coca-colacompany.com/news-events/press-releases/detail/1166/the-coca-cola-company-announces-technology-disruption-involving-fairlife-operations
[7] Coca-Cola Halts fairlife U.S. Production After Cyber Incident https://www.morningstar.com/news/dow-jones/202607169162/coca-cola-halts-fairlife-us-production-after-cyber-incident-update
[8] Iranian hackers’ targeting of US critical infrastructure has … https://www.reuters.com/world/middle-east/iranian-hackers-targeting-us-critical-infrastructure-has-escalated-since-start-2026-04-07/
[9] The Iranian Cyber Threat to U.S. Critical Infrastructure https://www.csis.org/analysis/iranian-cyber-threat-us-critical-infrastructure
[10] 10 Major Cyberattacks And Data Breaches In 2026 (So Far) – CRN https://www.crn.com/news/security/2026/10-major-cyberattacks-and-data-breaches-in-2026-so-far
[11] Iranian Cyber Actors May Target Vulnerable US Networks and … https://www.cisa.gov/sites/default/files/2025-06/joint-fact-sheet-Iranian-cyber-actors-may-target-vulnerable-US-networks-and-entities-of-interest-508c-1.pdf
[12] Top 10 Most Dangerous Cyber Attacks of 2026 (Explained & Visualized) https://www.youtube.com/watch?v=7ZEb80DRmqw
[13] Top 10 Common Cyber Attacks in 2026 and How to Prevent … https://factosecure.com/top-10-common-cyber-attacks-in-2026-and-how-to-prevent-them/
[14] 9. Code Injection Attacks https://cybersecuritynews.com/cyber-attacks-2026/
[15] Coca-Cola’s fairlife Pauses U.S. Production https://www.stocktitan.net/news/KO/the-coca-cola-company-announces-technology-disruption-involving-xrheubwqimy1.html

July 16, 2026

Disinflation Wins, Tech Whimpers: A Soft Landing With Hard Questions for Wall Street – July 16, 2026 -( $HPP $INTG $VIX $YSG Rise!)

U.S. markets closed broadly lower on Thursday, July 16, 2026, with a decisive risk‑off tone as investors rotated out of high‑beta growth and precious metals while volatility climbed.Market close: indices and risk sentimentThe S&P 500 (^GSPC) finished at 7,533.77, down 38.63 points or 0.51%, while the Dow Jones Industrial Average (^DJI) slipped to 52,552.97, a loss of 105.67 points or 0.20%. The Nasdaq Composite (^IXIC) led the downside, falling 387.28 points or 1.47% to 25,881.95, as profit‑taking hit semiconductor and AI‑linked leaders following a powerful year‑to‑date rally.Small‑cap equities were more resilient but still in the red, with the Russell 2000 (^RUT) closing at 2,974.57, off 1.69 points or 0.06%, highlighting modest de‑risking rather than wholesale capitulation in domestically focused names. The Cboe Volatility Index (VIX) jumped to 16.73, up 1.06 points or 6.76%, signaling a meaningful bid for downside protection as investors recalibrated positioning around earnings, inflation data, and Federal Reserve policy expectations.Macro and cross‑asset toneThe day’s weakness came against a backdrop of mixed but generally cooler producer‑price inflation, which has supported the “higher for longer, but done hiking” narrative even as near‑term growth and valuation concerns weigh on richly priced tech and chip names. Gold futures, a traditional safe‑haven asset, did not benefit from the equity pullback; instead, gold settled at 3,979.90, down 71.90 or 1.77%, underscoring the idea that today’s move was more about equity‑specific positioning than a broad flight to safety.In credit and rates, easing Treasury yields remain supportive of quality cyclicals and select financials, but the combination of rising VIX, weaker Nasdaq, and falling gold prices paints a picture of investors trimming risk exposure ahead of upcoming data and earnings catalysts rather than making a directional macro call.Earnings and sector narrativeThe sell‑off in the Nasdaq coincided with heightened focus on technology and communication‑services earnings, headlined by Netflix’s (NFLX) second‑quarter 2026 release, where investors are scrutinizing ad‑tier adoption, global subscriber trends, and margin durability. Semiconductor and AI infrastructure plays, represented by vehicles such as the iShares Semiconductor ETF (SOXX) and Invesco QQQ Trust (QQQ), faced pressure as traders reassessed premium multiples against a cooling but still restrictive macro backdrop.At the same time, breadth within the S&P 500 (SPY) remains bifurcated, with several constituents printing fresh 52‑week highs on strong execution while a smaller cohort sinks to lows, emphasizing that stock‑picking and narrative differentiation are critical in this environment.  

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $10.95.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $16.09, +3.61%) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.16 ) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.”   said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”

Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $3.24), a leader in innovative, patient-centric insulin delivery, released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.

Modular Medical (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $7.05), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR)act 5-days and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA)

NVIDIA (NVDA) closes at $207.40.

The InterGroup Corporation (NASDAQ: INTG)

The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $38.61, +1.07%.

LG Display Co., Ltd. (NYSE: LPL)

LG Display Co., Ltd. (NYSE: LPL, $3.38) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $3.70, +.82%), a world-class beauty innovation pioneer, announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $22.21) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

The Sources

  1. CNBC – “Stock market today: Live updates” (July 15–16, 2026)
    https://www.cnbc.com/2026/07/15/stock-market-today-live-updates.html
  2. CNBC – “Netflix (NFLX) earnings Q2 2026”
    https://www.cnbc.com/2026/07/16/netflix-nflx-earnings-q2-2026.html
  3. Yahoo Finance – “Stock market today, Thursday July 16: Dow, S&P 500, Nasdaq, chip stocks slide”
    https://finance.yahoo.com/markets/live/stock-market-today-thursday-july-16-dow-sp-500-nasdaq-chip-stocks-slide-103116735.html
  4. Globe and Mail – “Stock Market News for July 16, 2026”
    https://www.theglobeandmail.com/investing/markets/stocks/MS/pressreleases/3314969/stock-market-news-for-july-16-2026/
  5. Investopedia – “5 Things to Know Before the Stock Market Opens on Thursday, July 16, 2026”
    https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-on-thursday-july-16-2026-12020417
  6. Benzinga / Polymarket – “Stock Market: Will S&P 500 Open Up or Down Today? (July 16, 2026)”
    https://www.benzinga.com/markets/prediction-markets/26/07/60489078/sp500-july-16-open-up-or-down-polymarket-ppi-inflation-fed-re
  7. Trefis – “7/15/2026 Market Summary: 24 S&P 500 Stocks Hit Highs”
    https://www.trefis.com/data/companies/%5ESPX/no-login-required/n7pcmzWJ/7-15-2026-Market-Summary-24-S-P-500-Stocks-Hit-Highs-
  8. Trefis – “7/15/2026 Market Summary: 5 S&P 500 Stocks Hit Lows”
    https://www.trefis.com/data/companies/%5ESPX/no-login-required/fSGqxHxd/7-15-2026-Market-Summary-5-S-P-500-Stocks-Hit-Lows-
  9. HDFC Sky – “Stock Market Close Report, July 16, 2026: Sensex, Nifty Finish Flat As IT, Consumer Durables Offset Financial Weakness”
    https://hdfcsky.com/news/stock-market-close-july-16-2026-sensex-nifty-flat-it-consumer-offset-financial-weakness

July 16, 2026

Telehealth, Cryoplants, & Cash Flows: What PsiQuantum and Amwell May Mean for Long‑Horizon Investors -( $AMWL $BLK $NVDA )

Amid the AI boom, a quieter revolution is unfolding at the intersection of photons, silicon, and stethoscopes—and investors are starting to lean in.

From Qubits to Check‑Ups: Two Infrastructure Bets Hiding in Plain Sight

If Silicon Valley once ran on sand and software, the next decade may run on qubits and virtual care workflows. On one side of the Bay, PsiQuantum is attempting the technological equivalent of tightrope walking across the Grand Canyon in a headwind: building a one‑million‑qubit, fault‑tolerant quantum computer using standard semiconductor manufacturing and photonics. The company has raised more than 2 billion dollars, sports a valuation north of 7 billion dollars, and counts NVIDIA Corporation (NASDAQ: NVDA) and BlackRock, Inc. (NYSE: BLK) among the investors willing to fund that high‑wire act. On the other side of the country, American Well Corporation, doing business as Amwell (NYSE: AMWL), is pursuing a more prosaic mission that may prove just as consequential for returns: becoming the digital operating system for hybrid healthcare by connecting providers, payers, patients, and innovators through a single virtual care platform and hardware ecosystem.

One is building the machine that could one day redesign molecules; the other is wiring the messy, reimbursed, regulated reality of how care is actually delivered. Both share a common thread that tends to age well on Wall Street: if they work, they become foundational.

PsiQuantum: When “Exponential Money” Meets Industrial Pragmatism

PsiQuantum’s Milpitas facility is housed in what was once the last production chip fab in Silicon Valley, repurposed into a quantum factory that looks less like a lab experiment and more like a specialized data center with a cryogenic addiction. Co‑founder and Chief Scientific Officer Pete Shadbolt describes the company’s philosophy with the kind of deadpan that typically precedes large capital calls: “From the very beginning, we’ve just been pigheadedly interested in building million‑qubit‑scale machines.” Rather than chasing elegant lab demos, the team is designing around pre‑existing, high‑volume semiconductor and photonics supply chains—standard fabs, fibers, and off‑the‑shelf cooling infrastructure—while reserving the real innovation for the quantum stack itself. The core building block is a photonic module: a cluster of chips etched to guide light instead of electrons, creating qubits by sending single photons through waveguides and beam splitters, and reading them out with superconducting single‑photon detectors that can spot individual particles of light with roughly 99% efficiency. Roughly one hundred such modules, each carrying hundreds of chips, forms the skeleton of a million‑qubit machine, cooled by a massive helium‑based cryoplant—itself described as “basically the form factor” of the eventual system.

The investment case—and the risk—is temporal. There are, as Shadbolt notes with uncomfortable candor, “no useful quantum computers on the planet” today; existing systems are research tools with no commercial must‑have application. Yet consensus across much of the industry has converged around the end of this decade as the plausible window for the first fault‑tolerant, utility‑scale machines.

If that timeline holds, the payoff is not incremental productivity; it is category creation. At scale, quantum computers could radically reshape how we approach high‑value problems in chemistry, materials science, and finance—moving from today’s non‑deterministic, trial‑and‑error discovery processes toward more deterministic design of drugs, catalysts, fuels, and complex financial structures.

Shadbolt’s favored phrase is “a categorically new level of mastery over chemistry, physics, and math”—a line that reads like hype until you recall that every prior leap in compute has minted a new class of dominant platforms, from mainframes to cloud to AI accelerators. Whether PsiQuantum ultimately captures that value or merely proves the path for others is, for investors, the multi‑billion‑dollar question. For now, the presence of NVIDIA and BlackRock on the cap table signals that the “smart money” is at least willing to pay for a front‑row seat.

Amwell: The Quiet Plumbing of Hybrid Care

If PsiQuantum is chasing the future of physics, Amwell is focused on the far less glamorous, but immediately billable, business of making healthcare delivery work in a world where “in‑person” and “virtual” are no longer competing adjectives but adjacent tabs in the same clinical workflow.

Amwell positions itself not as a direct‑to‑consumer telehealth brand but as an enterprise platform that digitally empowers health systems, health plans, employers, and innovators to deliver care across the continuum—urgent, acute, post‑acute, behavioral, chronic, and even healthy living. Its Converge platform and Carepoint hardware effectively act as the connective tissue between physical facilities and digital touchpoints, allowing hospitals to transform telehealth from “video visits bolted onto the side” into an integrated, hybrid model of care. The scale is already non‑trivial. Amwell supports roughly 90 million members who have access to its services as a covered benefit, works with about 80 U.S. health systems, and has facilitated approximately 37.6 million virtual visits since inception. The company’s enterprise platform powers provider‑to‑provider virtual care for scenarios such as telestroke, virtual nursing, and e‑sitting, while its Carepoint carts, TV kits, and tablet‑based devices turn bedsides and clinical stations into digital access points.

From an investor’s perspective, this looks less like a pure “telehealth app” and more like a specialized software‑and‑devices infrastructure layer where switching costs reside not in a smartphone icon but in deeply embedded workflows, integrations, credentialing, and compliance. The company’s ESG and security posture—highlighting data privacy, information security certifications, and enterprise risk management—speaks directly to the procurement checklists of large health systems and payers. In other words, Amwell is trying to become the boring, indispensable middleware of modern care delivery. Wall Street has historically done well with boring and indispensable, once it learns to look past early‑stage losses and regulatory noise.

Why These Bets Rhymes With Prior Platform Shifts

Investors trying to map these stories onto familiar terrain could do worse than thinking in terms of “platform leverage.”

  • Quantum computing, if realized at scale, is not a feature; it is a new substrate for entire industries, especially those constrained by computational intractability—drug discovery, molecular modeling, optimization, and certain classes of financial modeling. In that world, equity in the earliest successful platform providers is functionally an option on a new compute regime..
  • Enterprise digital care platforms such as Amwell’s Converge are not point solutions; they are operating layers where many future services—from AI triage and automated chronic‑care programs to behavioral health modules—will eventually plug in. Equity here is an option on the normalization of hybrid care as a default model and the subsequent monetization of that traffic..

Thematically, both PsiQuantum and Amwell are infrastructure stories: one at the level of fundamental physics, the other at the level of regulated workflows. Both are also, in their own ways, anti‑fashion. PsiQuantum’s strategy is to avoid reinvention in everything that can be purchased off the shelf—from cryogenic pumps to photonic manufacturing—while saving its risk budget for the quantum stack. Amwell’s approach is to quietly re‑platform the unglamorous middle of healthcare delivery, far from the headline‑grabbing consumer apps.

For investors accustomed to AI narratives where each foundation model appears to demand “exponential money for linear progress,” there is a certain grim humor in Shadbolt’s gratitude that quantum does not share that particular pathology—at least not in the same way. Building a million‑qubit machine is still brutally hard, but the cost curve is tied more to industrial scaling than to endlessly retraining larger models on internet exhaust..

Positioning Around an Asymmetric Future

None of this absolves investors from the uncomfortable part: timing. Quantum remains pre‑revenue in any meaningful sense; telehealth remains exposed to policy, reimbursement, and macro cycles.

Yet the asymmetry is hard to ignore. If PsiQuantum or its peers deliver a fault‑tolerant photonic machine by decade’s end, the upside will likely accrue first to those who underwrote the long, unfashionable phase of hardware and fabrication risk. If Amwell succeeds in becoming the de facto orchestration layer for large swaths of hybrid care, its installed base of members, health systems, and devices becomes a distribution channel for future services in behavioral health, chronic disease management, and AI‑enabled “automated care” programs. In a market captivated by short‑term AI winners, there is room in a sophisticated portfolio for what might be called “patient infrastructure” bets—assets where the payoff profile looks less like a quarterly beat and more like optionality on the next epoch of compute and care. NVIDIA and BlackRock have already placed their chips on PsiQuantum, effectively signaling that quantum is graduating from whiteboard speculation to institutional diligence. Amwell, trading as AMWL on the New York Stock Exchange, is further along the commercialization curve, with real customers, real utilization metrics, and the very real headaches of operating in healthcare.

For investors willing to think beyond the current AI cycle, these two stories offer a simple, if slightly mischievous, framing: one is building the computer that may one day design the molecule that your doctor prescribes; the other is building the platform through which that doctor will actually deliver the visit. As always, the market will decide how to price that connective tissue. The question for portfolio constructors is whether they want to be long or merely entertained when it does.

Learn More From PsiQuantum

The Sources

  1. PsiQuantum – “Why NVIDIA & BlackRock Are Betting $2.3B on This Startup” (YouTube video)
    https://www.youtube.com/watch?v=2jshwfW6b4Q
  2. Amwell – About Us (company site)
    https://business.amwell.com/about-us
  3. Amwell – Overview Brochure (platform, devices, hybrid care details)
    https://cdn.prod.website-files.com/5bf603f84ae3426101807d56/609ae72c6a448737227ebfdb_Amwell%20Overview%20Brochure.pdf
  4. American Well Corporation (Amwell) – Company profile & facts (Yahoo Finance, AMWL)
    https://ca.finance.yahoo.com/quote/AMWL/profile/
  5. American Well Corp (AMWL) – Company information (HL)
    https://www.hl.co.uk/shares/shares-search-results/a/american-well-corp-usd0.01-a/company-information
  6. Amwell – Company overview and description (GlobalData)
    https://www.globaldata.com/company-profile/american-well-corp/
  7. Amwell – Leadership team and company positioning
    https://business.amwell.com/about-us/leadership-team

July 16, 2026

Wall Street On A Good Trip: Lilly, CareDx, And Eupraxia Rewrite The Biotech Script -( $ATAI $CDNA $EPRX $LLY )

Biotech’s latest plot twist has Wall Street grinning: a Big Pharma icon betting billions on psychedelics, a transplant diagnostics player finally getting its Medicare script approved, and a quietly ambitious drug-delivery innovator upgrading its cast of characters for the next act.

Lilly’s Psychedelic Pivot: From Prozac Era To AtaiBeckley

Eli Lilly and Company (NYSE: LLY) has decided that the future of depression treatment might look less like a pill bottle and more like a carefully choreographed psychedelic experience, agreeing to acquire AtaiBeckley (NASDAQ: ATAI) in a deal that could reach $3.8 billion. Lilly will pay $6.75 per share in cash, valuing the equity at roughly $2.8 billion upfront, with another potential $2.50 per share tied to clinical and regulatory milestones for lead programs BPL‑003 and VLS‑01. AtaiBeckley’s therapies aim to restore synaptic connectivity and promote new neural growth in treatment‑resistant depression, offering a distinct mechanism versus conventional selective serotonin reuptake inhibitors that have dominated psychiatry for decades. The market approved of Lilly’s change in mood: ATAI shares jumped about 30% in pre‑market trading as investors recognized that the psychedelic asset class is moving from counterculture to capital structure.

Why This Deal Matters: Psychedelics Go Mainstream

The Lilly–AtaiBeckley tie‑up signals that psychedelic medicine is graduating from early‑stage venture fascination to late‑stage Big Pharma integration. By tying a sizable portion of the consideration to regulatory and clinical milestones, Lilly is effectively pricing optionality on a category where clinical signal is robust but commercial and reimbursement pathways are still forming. For investors, the transaction reframes treatment‑resistant depression as a large, underpenetrated market where durable response and fewer hospitalizations could become powerful economic levers in payer models. It also suggests that neuroscience and psychiatric franchises may become strategic pillars again after years where oncology and immunology stole the spotlight.

CareDx: Transplant Diagnostics Finally Gets Its Policy Payoff

While Lilly is rewriting the depression chapter, CareDx, Inc. (NASDAQ: CDNA) is quietly resolving one of the biotech industry’s most persistent plot points: reimbursement certainty. Medicare has finalized its Local Coverage Determination (LCD) for molecular testing in solid organ allograft rejection, affirming coverage across CareDx’s transplant surveillance portfolio in kidney, heart and lung. The finalized LCD confirms coverage for offerings such as AlloSure Kidney and related surveillance tests, validating the clinical and economic role of non‑invasive molecular monitoring versus traditional biopsy‑heavy care. Unsurprisingly, CDNA shares jumped roughly 20% after the announcement, as investors marked up the value of a diagnostics platform now operating with far clearer visibility on utilization and payment.

Reading The CareDx Script: Revenue Quality Over Revenue Hopes

Medicare’s final LCD is not a mere footnote; it is a core part of the CareDx investment thesis. With bundled payments and defined indications, the policy helps translate clinical adoption into more predictable cash flows, a rare luxury in precision diagnostics. CareDx has also been sharpening its portfolio, recently completing the acquisition of Naveris to extend its reach into specialty oncology and cell therapy monitoring. For shareholders, the combination of an affirmed transplant reimbursement framework and expansion into higher‑growth oncology niches frames CDNA as a platform story rather than a single‑product wager.

Eupraxia Pharmaceuticals: Casting For The Next Act In Drug Delivery

Eupraxia Pharmaceuticals Inc. (TSX: EPRX, NASDAQ: EPRX) is taking a different path to investor relevance: build the team that can turn a clever technology into a durable franchise. The company recently strengthened its executive leadership, including appointments in senior management roles designed to support the next phase of growth around its proprietary Diffusphere™ drug‑delivery platform. Diffusphere™ is engineered to enable local, controlled and extended‑release delivery of existing and new drugs, with the aim of improving safety, tolerability and duration of effect in conditions such as osteoarthritis and eosinophilic esophagitis. Eupraxia has already completed a Phase 2 trial in knee osteoarthritis that met its primary endpoint and most secondary endpoints, and continues to advance pipeline programs like EP104GI in gastrointestinal indications. For investors accustomed to systemic therapies that deliver peak levels and collateral side effects, targeted local delivery with better therapeutic windows is a compelling, if still early, narrative.

Strategy In Three Scenes: Psyche, Graft, And Delivery

Seen together, Lilly, CareDx and Eupraxia illustrate three different but complementary ways capital is flowing into high‑conviction healthcare themes.

  • Lilly (LLY) is buying scale and optionality in a nascent therapeutic modality, wagering that psychedelic‑based neuroscience will become standard of care in subsets of depression.
  • CareDx (CDNA) is harvesting the value of years of clinical validation by securing payer policy that transforms tests into durable annuity‑like cash flows.
  • Eupraxia (EPRX) is building an execution engine around platform technology that could retrofit existing drugs with superior delivery, starting in pain and inflammatory disease.

For institutional and retail investors, the common thread is capital discipline around large, structurally growing markets—mental health, transplantation, and chronic inflammatory disease—rather than speculative niche biology.

Investor Takeaways: Where The Smart Money Is Looking

A few practical angles emerge for portfolio construction and idea generation.

  • Psychedelic psychiatry is transitioning from microcap experimentation to strategic Big Pharma exposure, making ATAI’s valuation and Lilly’s deal terms a reference point for future consolidation..
  • Transplant diagnostics are moving into a more mature phase where reimbursement is no longer the primary risk variable, which can justify higher multiples for cash‑flow‑generative platforms like CDNA.
  • Local, extended‑release delivery platforms such as Eupraxia’s Diffusphere™ create optionality across indications and partners, offering a levered way to play drug‑reformulation economics.

In a market still debating the direction of rates and the durability of the AI trade, these stories show that healthcare alpha may increasingly come from businesses that quietly fix the economics of care—whether by changing how we treat the mind, how we preserve transplanted organs, or how we deliver familiar molecules more intelligently.

The Sources

  1. Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy – Yahoo Finance
    https://finance.yahoo.com/markets/article/eli-lilly-to-buy-psychedelic-drugmaker-ataibeckley-for-up-to-38-billion-in-bet-on-depression-therapy-132324945.html
  2. Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal – Yahoo Finance / Reuters
    https://finance.yahoo.com/healthcare/articles/lilly-enters-psychedelic-drug-race-105046700.html
  3. Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion – CNBC
    https://www.cnbc.com/2026/07/16/eli-lilly-to-buy-psychedelics-maker-ataibeckley-2point8-billion.html
  4. Eli Lilly agrees to $3.8B psychedelic buy – Axios
    https://www.axios.com/2026/07/16/eli-lilly-ataibeckley-psychedelic-buy
  5. Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J in psychedelic mental health – FierceBiotech
    https://www.fiercebiotech.com/biotech/eli-lilly-inks-28b-ataibeckley-buyout-challenge-jj-psychedelic-mental-health-market
  6. CareDx shares jump as Medicare finalizes transplant testing coverage – Yahoo Finance
    https://finance.yahoo.com/healthcare/articles/caredx-shares-jump-medicare-finalizes-134325976.html
  7. CareDx announces finalization of solid organ transplant molecular testing Local Coverage Determination – MarketScreener
    https://www.marketscreener.com/news/caredx-announces-finalization-of-solid-organ-transplant-molecular-testing-local-coverage-det-xxxxx
  8. CareDx Finalizes Medicare Coverage for Transplant Testing – StockTitan
    https://www.stocktitan.net/news/CDNA/care-dx-announces-finalization-of-solid-organ-transplant-molecular-ck41pjx6ctk7.html
  9. CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 – Business Wire
    https://www.businesswire.com/news/home/20260716572560/en/CareDx-to-Report-Second-Quarter-2026-Financial-Results-on-July-30-2026
  10. CareDx Inc. – Investor Relations: News
    https://investors.caredx.com/news/default.aspx
  11. CareDx Inc. – Investor Relations: Quarterly results
    https://investors.caredx.com/financials/quarterly-results/default.aspx
  12. Eupraxia Pharmaceuticals Strengthens Executive Leadership Team – Yahoo Finance
    https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-strengthens-executive-leadership-200500204.html
  13. Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase – Nasdaq press release
    https://www.nasdaq.com/press-release/eupraxia-pharmaceuticals-strengthens-executive-leadership-team-support-next-phase
  14. Eupraxia Pharmaceuticals Strengthens Senior Management Team – Yahoo Finance
    https://finance.yahoo.com/news/eupraxia-pharmaceuticals-strengthens-senior-management-210100570.html
  15. Eupraxia Pharmaceuticals – Investor relations: News releases
    https://investors.eupraxiapharma.com/news-events/news-releases

July 16, 2026

From 34% Vacancy to a 30-Year Leasing Record: The San Francisco Commercial Real Estate ‘Boom Loop’ Turnaround ‘Nobody’ Predicted – ( $HPP $INTG )

The city that perfected the art of the doom loop is now quietly engineering a boom loop, one square foot at a time.

San Francisco has spent the better part of five years being the cautionary tale at every commercial real estate conference — the city where office vacancy soared past 34%, where “For Lease” signs outnumbered coffee shops, and where consultants earned handsome fees advising clients to look literally anywhere else. Then the artificial intelligence revolution arrived, set up shop in Mission Bay and South of Market, and proceeded to make everyone look a little silly. The City, it turns out, was not just unprepared for the AI boom. It was spectacularly, almost poetically unprepared — and that, for contrarian investors paying close attention, made it one of the most interesting real estate stories in America.

From Doom Loop to Boom Loop: The Numbers That Changed Everything

The turnaround has been swift enough to cause whiplash. In 2025, San Francisco’s office market recorded 10.2 million square feet in leases — the highest volume since 2019 — with AI companies now occupying roughly 7 million square feet, approximately 12% of total occupied office space. The vacancy rate, which peaked at a jaw-dropping 34.4%, has since fallen to approximately 28% as of Q2 2026 — a 320-basis-point improvement from its Q2 2025 peak, per Colliers. The first quarter of 2026 set yet another record: tenants leased roughly 3 million square feet, AI companies accounting for nearly 40% of deal volume, with more than 370 prospective tenants entering the San Francisco market between January and March — the most VTS had tallied in over a decade. By mid-2026, leasing volume for the first half of the year reached approximately 6.4 million square feet, and at that pace, full-year activity is projected to approach 15.3 million square feet — a figure that would rival San Francisco’s 1996 peak, per Newmark. Venture capital funding in San Francisco reached $252 billion in just the first five months of 2026, more than double the $117 billion raised during all of 2025. The AI ecosystem is also minting wealth. OpenAI and Anthropic, both headquartered in San Francisco, have filed to go public at valuations approaching $1 trillion each, promising to mint a new class of multimillionaires in a city already holding the highest concentration of billionaires per capita in the world. The residential market responded accordingly: more than 140 homes sold for at least $1 million above asking price in just the first half of 2026, compared to just six in the same period of 2024, according to a Compass analysis. Compass Chief Economist Mike Simonsen called the dynamic “absolutely BANANAS“.

Hudson Pacific Properties (HPP): Patience Rewarded With a Record-Setter

For investors wondering how to play this commercial real estate recovery, Hudson Pacific Properties, Inc. (NYSE: HPP) recently delivered a compelling data point. In June 2026, Hudson Pacific executed a 502,082-square-foot, 23-year lease with the City and County of San Francisco at 1455 Market Street — the largest office lease signed in San Francisco since 2018. The deal brings occupancy at the approximately 1-million-square-foot, 22-story LEED Gold-certified tower to 89%, with the City’s total footprint in the building exceeding 900,000 square feet through 2049, plus two five-year extension options. Several city departments — including the Municipal Transportation Authority, the Human Services Agency, and the City Administrator — will consolidate into the tower, moving out of what officials described as “aging, costly and seismically vulnerable” facilities. The building itself is a study in long-term conviction. Hudson Pacific originally acquired 1455 Market for $93 million in 2010, watched its valuation collapse to roughly $96.6 million by 2024 — an 80% haircut from its 2015 peak of $219.2 million — and then held on as San Francisco’s office market rewrote its own obituary. The lease reset rents at approximately $40 per square foot, replacing a previously negotiated higher-escalation schedule, and includes a city purchase option that effectively creates a multi-decade public-private partnership with significant optionality baked in. For HPP shareholders, this is exactly the kind of government-backed, long-duration anchor that REIT investors prize — and it signals that the company’s San Francisco thesis is playing out, if on a timeline that tested all but the most patient holders.

The InterGroup Corporation (INTG): A Boutique Play on San Francisco’s Hospitality Revival

If Hudson Pacific represents the institutional grade of the commercial comeback, The InterGroup Corporation (NASDAQ: INTG), through its majority-owned subsidiary Portsmouth Square, Inc., tells a quieter but compelling story about what happens when San Francisco’s hospitality market rediscovers its footing. InterGroup owns the 544-room Hilton San Francisco Financial District — a property that spent several years nursing significant debt obligations and going-concern uncertainty before the city’s AI-powered revival changed the math. The fiscal third quarter ended March 31, 2026 delivered a decisive inflection: total revenues reached $20.4 million, a 21% year-over-year increase, while hotel revenues surged 35% to $16.5 million. The Hilton San Francisco Financial District posted an ADR of $306, occupancy of 94%, and RevPAR of $287, compared to $241, 89%, and $215 respectively in the prior-year quarter. Income from operations rose 81% to $4.3 million, and net income attributable to InterGroup came in at $0.46 million, or $0.21 per diluted share — a decisive swing from a loss of $0.27 per share in the same period a year earlier. The Super Bowl hosted in San Francisco during the quarter provided a demand catalyst alongside the broader structural tailwind of AI-sector hiring and return-to-office mandates. Full-year fiscal 2025 EBITDA surged 131.7% year-over-year to $13.2 million. InterGroup further bolstered liquidity through the December 2025 sale of a non-core 12-unit Los Angeles multifamily property for approximately $4.85 million, generating a $3.5 million GAAP gain and $2.58 million in net cash proceeds. The hotel segment is increasingly carrying the narrative — and that narrative is getting better every quarter.

The Infrastructure Paradox: Unprepared in More Ways Than One

There is a wrinkle in San Francisco’s triumphant return that investors should monitor. Trophy-class office vacancy had fallen to approximately 5% by mid-2026, with rents for premium spaces reaching $140 per square foot — a 40% increase year-over-year, per JLL. Available sublease space has dropped from nearly 10 million square feet in mid-2023 to approximately 3.4 million square feet today, as venture-backed firms increasingly prioritize move-in-ready space. The same AI boom filling offices is straining the power grid running the data centers behind those offices. Some data center projects have already been shelved due to community resistance and grid capacity constraints. Infrastructure — not capital — is becoming the new bottleneck, and as Colliers noted, investment is becoming “increasingly bifurcated — AI-driven sectors expanding while traditional industries lose momentum”. New development is cautiously emerging: Related California’s 41-story office tower near Jackson Square is one tenant agreement away from breaking ground, and CBRE’s Colin Yasukochi projected major South of Market construction starting by 2027 — a speculative groundbreaking in a market still carrying a 28% vacancy rate that perfectly encapsulates what makes San Francisco’s story unlike anywhere else in the country.

What Investors Should Be Watching

The convergence of three storylines — San Francisco’s AI-fueled office demand, Hudson Pacific’s landmark lease, and InterGroup’s hospitality revival — paints a picture of a market recovering unevenly but recovering unmistakably. CBRE projects AI companies could occupy 21 million square feet in San Francisco by 2030, potentially cutting the city’s vacancy rate in half, while 50,000 to 60,000 new jobs could be added to the local economy over the same period. San Francisco was indeed “totally unprepared” for what is happening. The infrastructure gaps are real, the recovery remains K-shaped, and the city’s storied ability to complicate its own success should never be underestimated. But for investors who can read between the vacancy statistics and see the structural forces underneath, the city that spent five years as everyone’s favorite cautionary tale may be quietly becoming one of the most interesting commercial real estate turnaround opportunities in a generation.

The doom loop had a sequel. They’re calling it the boom loop — and the cast includes some very large leases, one patient REIT, and a Financial District hotel that just posted a 94% occupancy rate.

The Sources

Here are all the sources used in the story, in numerical order:

  1. JLL — “Betting Big on San Francisco’s Office Market Turnaround”
  2. The Guardian — “‘Absolutely Bananas’: San Francisco Homes Sell for $1M Above Asking Price Amid AI Boom”
  3. Yahoo Finance — “InterGroup Third Quarter 2025 Earnings”
  4. Business Wire — “Hudson Pacific Executes 502,000-Square-Foot, 23-Year Lease with City and County of San Francisco”
  5. CBRE — “AI Boom Drives Office Leasing Surge in San Francisco Bay Area”
  6. Forbes Finance Council — “Will AI Lead to a Rebound for Commercial Real Estate?”
  7. The Real Deal SF — “SF’s Office Market Hits Mark Not Seen Since 2011”
  8. PwC — “San Francisco AI Growth and Real Estate Market Trends”
  9. SF Chronicle — “Tech Boom Fuels S.F.’s Best Year for Office Leasing Since 2019”
  10. The Registry SF — “Silicon Valley Commercial Real Estate Market Expected to Thrive in 2026 and Beyond”
  11. Nasdaq — “Hudson Pacific Executes 502,000-Square-Foot, 23-Year Lease with City and County of San Francisco at 1455 Market”
  12. The Real Deal SF — “Hudson Pacific Lands SF’s Biggest Office Lease in Nearly a Decade”
  13. MarketScreener — “The InterGroup Corporation Reports Fiscal Year 2025 Results”
  14. The Dissent SF — “Bay Area Office Vacancies Fall in Q2 as AI, Tech Firms Take Up Millions of Square Feet”
  15. The Real Deal SF — “San Francisco Eclipses New York in Office Recovery”
  16. The Real Deal SF — “SF Office Vacancy Rate Shrinks as Demand from AI Firms Picks Up”
  17. Daily REIT Beat / X — “Hudson Pacific Properties Lands Massive Lease at 1455 Market”
  18. StockTitan — “InterGroup Posts Profit, Sells LA Multifamily Asset”
  19. Allwork.Space — “AI Tenants Power San Francisco Office Market Recovery After Years of Slump”
  20. The Real Deal SF — “SF Office Boom Spreads South as Silicon Valley Vacancy Falls”
  21. Yahoo Finance — “InterGroup Swings to Earnings in Q3 on Improved Hotel Revenues”
  22. Investing.com — “InterGroup Reports 21% Revenue Rise in Fiscal Q3”
  23. The Real Deal SF — “SF Office Leasing Activity Rides AI Wave to Near 30-Year High”
  24. The Real Deal SF — “SF AI Office Boom Meets Immigration Labor Warning”
  25. LinkedIn / Vistaaraihub — “AI Drives Office Demand in SF, But Infrastructure Becomes Bottleneck”

Informational purposes only. Not investment advice. Tickers referenced: HPP (NYSE), INTG (NASDAQ).

The Sources

July 16, 2026

When Inflation Starts to Chill: Wall Street Turns Up the Heat – July 15, 2026 Market Wrap -( $AMWL $EPRX $JPM $LPL $SMWB Rise!)

U.S. stocks pushed higher again on Wednesday, July 15, 2026, as investors leaned into a “lower‑inflation, still‑resilient growth” narrative that is increasingly defining mid‑summer trading. Cooling CPI data, a more patient Federal Reserve outlook, and better‑than‑expected earnings from big banks and AI‑linked tech helped extend the post‑CPI rally across major benchmarks.

A risk‑on close across major indices

By the closing bell, the S&P 500 Index (SPX) had climbed to 7,572.40, up 28.81 points or 0.38%, marking another session where broad market breadth supported the headline move rather than just a handful of megacaps. The Dow Jones Industrial Average (DJIA) finished at 52,658.64, gaining 150.37 points or 0.29%, as money‑center banks and cyclical industrials led within the price‑weighted gauge.

Growth and tech leadership re‑emerged as the Nasdaq Composite (IXIC) advanced to 26,269.23, a gain of 162.22 points or 0.62%, with semiconductors and AI‑exposed software pacing the climb. Small caps joined the risk bid as the Russell 2000 (RUT) added 11.50 points to close at 2,976.26, up 0.39%, a constructive sign that participation is widening beyond the usual large‑cap franchises.

Volatility continued to bleed lower: the CBOE Volatility Index (VIX) fell to 15.67, down 0.83 points or 5.03%, underscoring a drop in demand for near‑term downside protection as investors grew more comfortable with the macro backdrop. In cross‑asset trade, gold eased slightly to $4,066.90 (‑0.07%), while Bitcoin (BTC‑USD) firmed to $64,819.85 (+0.29%), signaling a mild rotation away from traditional havens and a steady bid for digital risk assets.

Inflation “melts” and the Fed steps back from the brink

Underpinning the move was the evolving inflation storyline. June CPI delivered a rare monthly decline in headline prices, driven largely by softer energy, while core CPI slid toward the mid‑2% range year over year. That pattern has given markets a narrative they like: inflation is not only slowing, it is beginning to “melt” back toward the Fed’s comfort zone.

Rate expectations followed suit. Futures markets have increasingly priced out a near‑term hike, instead favoring an extended pause as policymakers weigh clear disinflation progress against an economy that has yet to show meaningful signs of stress. Treasury yields drifted lower across the curve, offering a tailwind to long‑duration growth names and supporting the premium investors are willing to pay for visible earnings and secular themes like AI.

Banks, BlackRock and AI set the tone

The earnings tape helped validate the macro optimism. Financials outperformed as money‑center banks reported robust trading and investment‑banking results. Goldman Sachs Group Inc. (GS), JPMorgan Chase & Co. (JPM), and Bank of America Corp. (BAC) extended recent gains on better‑than‑expected profitability, reinforcing the idea that capital‑markets activity remains healthy even as credit conditions normalize.

Asset‑manager BlackRock Inc. (BLK) benefited from solid flows into both index and active strategies, highlighting how scaled platforms continue to capture wallet share when risk appetite returns. In technology, investors stayed focused on AI and semiconductors. Companies with clear visibility into data‑center build‑outs and high‑bandwidth memory demand drew strong support, while legacy enterprise IT players such as International Business Machines Corp. (IBM) remained under pressure after a sharp post‑earnings drawdown. The market is increasingly distinguishing between firms where AI is a tangible revenue driver and those where it is still largely an aspirational story.

What today’s tape means for positioning

Today’s action points to a constructive environment for quality equities leveraged to AI infrastructure, semiconductors, and capital‑markets activity, provided the disinflation trend holds and the Fed stays data‑dependent rather than pre‑emptive. Lower volatility, easing yields, and broad‑based equity gains argue for maintaining core equity exposure, while using duration and options strategically to hedge against two key risks: a renewed energy‑driven inflation flare‑up or an escalation in geopolitical tensions that could disturb the current calm.

Looking ahead, the next leg of the story will be written by earnings from megacap technology, diversified financials, and healthcare/biotech. Those reports will help determine whether the present “lower inflation, resilient growth” regime can sustain further multiple expansion into the back half of 2026—or whether markets will need to recalibrate their optimism as the data and corporate guidance roll in.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $11.03, +1.38%.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.52, +2.84%) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.”   said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”

Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $4.19), a leader in innovative, patient-centric insulin delivery, released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.

Modular Medical (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $7.36, +10.76%), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR)act 5-days and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA)

NVIDIA (NVDA) closes at $211.80, +4.06%.

The InterGroup Corporation (NASDAQ: INTG)

The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $38.20.

LG Display Co., Ltd. (NYSE: LPL, $3.55, +1.14%) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story

The Sources

  1. CNBC – “Stock futures are flat after soft inflation reading lifts market: Live updates”
    [https://www.cnbc.com/2026/07/14/stock-market-today-live-updates.html
  2. Reuters – “Melting core: What matters in U.S. and global markets today”
    [https://www.reuters.com/commentary/reuters-open-interest/global-markets-view-usa-2026-07-15/
  3. HDFC Sky – “The Prime Daily 15 July 2026”
    [https://hdfcsky.com/news/the-prime-daily-15-july-2026
  4. U.S. Bureau of Labor Statistics – July 2026 release calendar (CPI, PPI, Real Earnings)
    [https://www.bls.gov/schedule/2026/07_sched_list.htm
  5. CNBC – S&P 500 Index quote page (.SPX)
    [https://www.cnbc.com/quotes/.SPX
  6. Yahoo Finance – S&P 500 Index (^SPX) historical data
    [https://finance.yahoo.com/quote/%5ESPX/history/][finance.yahoo]
  7. Nasdaq – Nasdaq Composite Index (COMP) market activity and historical data
    [https://www.nasdaq.com/market-activity/index/comp/historical

July 15, 2026

Unbeatable Spain, Unbathable Baby: How Lamine Yamal Turned A Messi Bathtub Cameo Into Football Alpha

Spain’s shutout of France, Lionel Messi’s march with Argentina toward yet another World Cup final, and Lamine Yamal’s improbable baby‑photo link to the GOAT now intertwine into a single narrative that looks suspiciously like a long‑term growth chart for global football—and for the business that feeds on it.

From UNICEF Bathtub To World Cup Spotlight

In October 2007, a 20‑year‑old Lionel Messi posed for a UNICEF calendar photo with a three‑month‑old baby whose family had won a raffle; that baby was Lamine Yamal, now Barcelona’s 18‑year‑old winger and Spain’s generational hope. The photographer later joked that the odds were akin to “Michael Jordan giving a bath to LeBron James,” a metaphor tailor‑made for investors who appreciate how compound probability—and compound talent—can reshape an entire asset class. Fast‑forward: Messi becomes the benchmark of a footballing era, while Yamal has emerged as a high‑beta growth stock, orbiting FC Barcelona’s La Masia academy and Spain’s national‑team system. Yamal’s current deal at Barcelona, reportedly worth tens of millions per year and paired with the iconic No. 10 shirt, signals management’s cash‑flow expectations from his blend of performance, brand power, and future media rights. What began as a charming UNICEF photo now reads like the first frame in a multi‑decade prospectus on how value is manufactured in modern sport.

Spain’s All‑Weather Model Vs. Superstar Risk

Spain’s 2‑0 victory over France in Dallas was the soccer equivalent of a well‑executed factor tilt rather than a chaotic meme‑trade rally. La Roja have now eliminated France in three consecutive semifinals—Euro 2024, Nations League 2025, and the 2026 World Cup—while running up a 37‑match unbeaten streak and outscoring seven World Cup opponents 13‑1 with six clean sheets. Manager Luis de la Fuente describes the formula as “discipline, being organized, with sacrifice, with commitment, with effort,” and he traces it directly to Spain’s academy ecosystem, where players are trained to “interpret and read the game” in all phases. That isn’t just coaching philosophy; it’s a national R&D program, visible in a bench that includes Pedri, Nico Williams, and Mikel Merino, and a tactical framework that doesn’t require Yamal to carry all the expected goals on his teenage shoulders. On the other side of the trade, Kylian Mbappé—France’s superstar forward and Real Madrid’s attacking centerpiece—arrived in the semifinal with eight goals, only to leave with zero shots on target, a yellow card, and the look of someone discovering that past performance really is no guarantee of future results. For investors, Spain’s model is a live case study in how a diversified, systems‑driven portfolio can neutralize concentrated superstar risk.

FC Barcelona: Talent Factory, Local Story, Global IP

At club level, FC Barcelona’s La Masia is behaving less like a simple academy and more like a venture studio for football talent. Yamal was spotted at age six, became the youngest player in Barça’s 126‑year history when he debuted at 15, and at 18 has already finished second in the Ballon d’Or while turning seasoned defenders into recurring viral content. His story runs through Roa Fonda, a struggling immigrant neighborhood on the outskirts of Barcelona where he grew up, with a pitch of hard concrete and graffiti calling for “more Lamine Yamals and fewer evictions.” His uncle’s café, LY304, takes its name from the local zip code that Yamal flashes with his hands after scoring, a detail that anchors his global rise in a very specific place and community. When he signed his latest contract, his extended family—including the grandmother who hid his first pair of boots in a closet—filled the club office, highlighting the social capital behind the on‑field asset. The 60 Minutes segment multiplies the monetization layers: dramatic footage of Yamal slaloming through “a gaggle of grown men,” commentators comparing his movement to a dragonfly changing direction mid‑flight, and the “uncut diamond” label that may eventually make its way onto a boot or apparel line. For rights holders and sponsors, that combination of visual spectacle and grounded backstory is not just entertainment; it is durable intellectual property.

Messi, Mbappé, Yamal And A Semi‑Final For The Ages

While Spain methodically closed out France, the bracket on the other side set up an England–Argentina semi‑final that feels more like a derivatives market, with layers of historic narrative priced into every tackle. England arrived in Atlanta by surviving Norway 2‑1 after extra time, powered by a brace from Jude Bellingham, who followed in a rebound to seal the win in the added period. Argentina, the defending champions led by Messi, booked their semi‑final place with a 3‑1 extra‑time victory over Switzerland in Kansas City. Alexis Mac Allister opened the scoring, Switzerland’s Dan Ndoye equalized, and then Julián Álvarez and Lautaro Martínez produced decisive goals in extra time to push la Albiceleste through. The Athletic’s live coverage and other outlets framed the England–Argentina clash as another chapter in a rivalry that includes the “Hand of God” and one of the greatest solo goals in World Cup history. For Messi, this semi‑final is an opportunity to extend a run that already includes scoring in seven consecutive World Cup matches and to keep Argentina on track to become the first back‑to‑back winners since Brazil in 1962. For England, it is a chance to break through historic glass ceilings and convert the Bellingham‑led core into something more than a promising spreadsheet of underlying metrics. In market terms, England vs. Argentina offers a neat contrast: England as an improving blue‑chip with decades of underperformance memories priced in, Argentina as a fully valued champion still compounding returns, and Spain—already through to the final—as the patient, system‑driven fund quietly beating them both on risk‑adjusted metrics.

Investor Themes: Where Capital And Story Converge

Taken together—the baby‑photo connection between Messi and Yamal, Spain’s “unbeatable” run, and the England–Argentina semi‑final—several investable themes emerge for readers who traffic in listed equities, private deals, and rights‑driven vehicles.

  • System over star. Spain’s 13‑1 goal differential and six clean sheets at this World Cup demonstrate how a disciplined system with academy‑fed depth can outperform a strategy built primarily around single‑name brilliance. In equities, this argues for diversified, process‑driven portfolios over concentrated bets on glamorous narratives.
  • Narrative as asset class. The UNICEF photo, the Roa Fonda graffiti, the LY304 café, and a teenager with braces dominating defenders on global television form a narrative stack that drives engagement far beyond match results. Rights holders, broadcasters, and sponsors that can structure, protect, and leverage these stories stand to capture long‑tail value.
  • Talent compounding. Yamal’s trajectory—from concrete pitch to La Masia to 60 Minutes and a World Cup final at 18—illustrates how early identification, structured development, and social support can compound both human and financial capital. The Messi arc shows what happens when that compounding runs for nearly two decades; investors in youth systems, analytics platforms, and scouting technology will see obvious parallels.
  • Risk management in rivalries. Mbappé’s muted semifinal and the knife‑edge nature of England–Argentina remind us that even the most electric assets carry drawdown risk when they collide with well‑prepared opposition. That is an elegant prompt to examine concentration in any portfolio over‑indexed to a single theme, sector, or personality.
  • Global rights and regional hubs. With Spain–France in Texas, Argentina–Switzerland in Kansas City, and England–Argentina in Atlanta, the 2026 World Cup showcases how North American venues anchor global narratives. From media deals to hospitality, the tournament functions as a real‑time stress test for regional infrastructure as a platform for international sports IP.

Spain now waits in the final, with Luis de la Fuente declaring that when teams face his side “we’re unbeatable,” a statement that sounds less like locker‑room bravado and more like an executive summary of a multi‑year strategy in footballing excellence.

The Sources

  1. CBS News – “Lamine Yamal: The 60 Minutes Interview”
    https://www.youtube.com/watch?v=d_b8EAKSrAw
  2. Fox Sports – “Spain feeling ‘unbeatable’ after shutting out France to reach World Cup final”
    https://www.foxsports.com/stories/soccer/spain-feeling-unbeatable-after-shutting-out-france-reach-world-cup-final
  3. Yahoo Sports – Lionel Messi / Lamine Yamal baby‑photo feature
    https://sports.yahoo.com/articles/lionel-messi-once-bathed-baby-165640404.html
  4. Argentina vs Switzerland – 2026 World Cup coverage (example: Athletic / bracket reference)
    https://www.nytimes.com/athletic/live-blogs/argentina-vs-switzerland-live-updates-world-cup-2026-score-result-messi/HROF42ljYNsP
  5. World Cup 2026 semi‑final preview – England vs Argentina (neutral preview site)
    https://footballpath2026.com/fixtures/england-vs-argentina-semi-final/
  6. Rivalry and bracket context – England vs Argentina semi‑final build‑up
    https://www.vanguardngr.com/2026/07/england-argentina-to-renew-bitter-rivalry-in-world-cup-semi-final-2/
  7. Match logistics – England vs Argentina semi‑final venue, date, and time
    https://footballpath2026.com/fixtures/england-vs-argentina-semi-final/
  8. France 24 – “England to face Argentina in tense semi‑final” (Argentina 3–1 Switzerland match report)
    https://www.youtube.com/watch?v=qoRXRsM0oTA
July 15, 2026

LG Display’s Game On: How LPL Turned OLED, CES 2026, And Gaming Obsession Into A Turnaround Story -( $LPL)


From “world’s first” Gaming OLED panels to CES 2026 awards, LG Display Co., Ltd. (NYSE: LPL) is quietly rewiring its business for higher‑quality growth – and retail investors now have front‑row seats.

LG Display Co., Ltd. (NYSE: LPL) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

From TV Commodity To Gaming OLED Specialty

At the heart of the LPL turnaround is a simple idea that many investors can appreciate: move away from low‑margin, crowded markets and double down where performance and specs matter. LG Display’s recent announcements highlight “world’s first” Gaming OLED panels with ultra‑high refresh rates, laptop OLED screens with wide variable refresh ranges, and certification‑winning color and brightness performance. For gamers and content creators, these aren’t just buzzwords – they are measurable advantages. For shareholders, they point to products that can justify better pricing and healthier margins. This is where the Gaming OLED angle really matters. Gamers are notoriously picky and willing to pay for smoother motion, better black levels, and more immersive visuals. By owning the innovation narrative in this niche, LG Display is effectively staking out premium real estate in a market where willingness to pay is structurally higher. Retail investors looking at LPL aren’t just buying “another screen company” – they’re buying into a spec‑driven arms race that favors whoever can stay one step ahead.

CES 2026: Turning Tech Bragging Rights Into Investor Signals

If Gaming OLED is where the technology story starts, CES 2026 is where it goes prime time. LG Display’s showcase at CES 2026 featured its “ultimate Gaming OLED” lineup alongside advanced automotive display solutions – and the company walked away with multiple CES Innovation Awards. Those awards matter because they validate the quality and uniqueness of LPL’s products in front of the global tech community, not just in a lab. For many investors, CES 2026 is more than a trade show; it’s a public scoreboard. When LG Display wins on that stage, it reinforces that the technology pivot is real, visible, and appreciated by industry insiders. Pair that with ongoing certifications for “Perfect Color/Brightness” and automotive display safety and cybersecurity, and you get a narrative where LG Display is not just competing – it is setting standards.

The Turnaround Angle: Numbers Behind The Narrative

Any turnaround story needs more than clever branding, and LPL’s recent financial releases show early proof points. While headline revenue has been pressured as the company phases out legacy LCD TV panels, operating profit and EBITDA have improved as the mix shifts toward OLED and higher‑value display segments. Many investors don’t need to memorize every won figure to grasp the trend: LG Display is working to make more profit from fewer but better businesses. That’s the key to the LPL turnaround angle. A company can shrink its way to health if what remains is structurally more profitable and better aligned with future demand. Gaming OLED, premium IT displays, and sophisticated automotive panels fit that bill. As those businesses scale, the potential for more stable, higher‑quality earnings grows – and that’s exactly the type of story long‑term investors tend to gravitate toward.

Why This Matters To Investors Now

For many investors, the appeal of LG Display’s LPL story comes down to three things:

  • It’s understandable.
    The pivot from low‑margin LCD to high‑margin OLED, especially in gaming and automotive, is a straightforward narrative that does not require a PhD in semiconductor physics.
  • It’s visible.
    CES 2026 awards, “world’s first” product announcements, and certifications give regular investors tangible milestones to follow as the strategy unfolds.
  • It’s potentially compounding.
    As more Gaming OLED panels ship, more OEMs adopt LG Display’s technology, and more awards and certifications stack up, the company’s positioning strengthens – which can support better pricing, better margins, and better long‑term returns if execution continues.

For some portfolios, LPL potentially can be viewed as a way to get exposure to several powerful themes at once: the rise of high‑refresh Gaming OLED, the digitization of vehicle interiors, and the broader shift from commodity hardware to performance‑driven display solutions. It’s still a cyclical business, and volatility in consumer electronics demand will show up in the numbers, but the direction of travel – toward better products and better economics – is what gives the turnaround narrative its investor magnetism.

What To Watch Next For LG Display (LPL)

1. Upcoming Quarterly Results
Many investors should keep an eye on LPL’s next earnings release and conference call for updated data on OLED mix, Gaming OLED shipments, and automotive display momentum. Management commentary on margins and demand trends in gaming monitors, laptops, and auto panels will be critical for confirming the turnaround trajectory.

2. New Gaming OLED Announcements
Watch for fresh product launches or “world’s first” Gaming OLED panels, especially around major tech events and gaming expos. Each new high‑refresh or performance‑certified panel strengthens LG Display’s premium positioning and can support better pricing and brand recognition with gamers and PC OEMs.

3. CES‑Style Innovation And Awards
While CES 2026 was a major showcase, similar trade shows and industry conferences (display, automotive, and gaming) can bring new awards or recognition for LG Display’s OLED and automotive solutions. Continued third‑party validation – innovation awards, certifications, and design wins – is a key signal that the technology pivot is sticking.

4. Automotive Display Design Wins
As more automakers upgrade to larger, more advanced in‑car displays, pay attention to announcements that link LG Display’s panels to specific vehicle platforms or OEM partnerships. Design wins in EVs and premium models can drive multi‑year revenue streams and reinforce the “higher‑quality growth” thesis for LPL.

5. Mix Shift Away From Legacy LCD
In future updates, look for signs that legacy LCD exposure is shrinking further while OLED, Gaming OLED, and advanced IT/automotive panels are taking a larger share of revenue. A sustained shift in mix, accompanied by stable or improving operating margins, is one of the most important metrics for evaluating the success of the turnaround story.

The Sources

  1. LG Display Co., Ltd. (LPL) quote page – Yahoo Finance
    https://finance.yahoo.com/quote/LPL/
  2. LG Display Q1 2026 earnings snapshot – Investing.com
    https://www.investing.com/news/company-news/lg-display-q1-2026-slides-oled-hits-60-of-revenue-amid-decline-93CH-4631225
  3. LG Display Q1 2026 earnings call highlights – Yahoo/Market coverage
    https://finance.yahoo.com/markets/stocks/articles/lg-display-co-ltd-lpl-070055702.html
  4. LG Display Reports First Quarter 2026 Results – LG Corp media release
    https://www.lgcorp.com/media/release/30091
  5. LG Display third‑quarter 2025 results – LG Display latest news
    https://www.lgdisplay.com/eng/company/media-center/latest-news?contentId=5474
  6. LG Display CES 2026 Gaming OLED lineup overview – LG Display Newsroom
    https://news.lgdisplay.com/en/2025/12/ces-2026-lg-display-worlds-first-best-gaming-oled-lineup-unveiled/
  7. LG Display showcases wide lineup of world‑first OLED monitors (CES 2026) – LG Display Newsroom
    https://news.lgdisplay.com/en/2025/12/lg-display-showcases-wide-lineup-of-world-firstleading-oled-monitors/
  8. LG Display begins mass production of “ultimate Gaming OLED” panel – LG Display Newsroom
    https://news.lgdisplay.com/en/2025/06/lg-display-begins-mass-production-of-ultimate-gaming-oled-panelwith-4th-generation-oled-tech/
  9. LG Display to mass‑produce world’s first Gaming OLED panel with switchable refresh rate – LG Display Newsroom
    https://news.lgdisplay.com/en/2024/04/lg-display-to-mass-produce-worlds-first-gaming-oled-panel-with-switchable-refresh-rate-and-resolution/
  10. LG Display to showcase world’s largest Gaming OLED lineup in Taiwan – PR Newswire
    https://www.prnewswire.com/news-releases/lg-display-to-showcase-worlds-largest-gaming-oled-lineup-in-taiwan-302785308.html
  11. LG Display SEC filings (including 6‑K and 20‑F references) – StockTitan
    https://www.stocktitan.net/sec-filings/LPL/
  12. LG Display earnings dates and report history – Investing.com UK
    https://uk.investing.com/equities/lg-display-co-earnings
  13. LG Display’s automotive display growth ambitions – BusinessKorea (premium car display market share)
    https://www.businesskorea.co.kr/news/articleView.html?idxno=200270
  14. LG Display leads premium automotive display market with record share – BusinessKorea
    https://www.businesskorea.co.kr/news/articleView.html?idxno=220485
  15. LG Display pivot to higher‑margin car and phone displays – Pulse (Maeil Business Newspaper)
    https://pulse.mk.co.kr/news/english/10702910
  16. LG Display aims to be top automotive display supplier – The Korea Times
    https://www.koreatimes.co.kr/www/tech/2025/02/129_171179.html
  17. LG Display (LPL) beats Q2 EPS estimates with strong profit growth – Yahoo/markets coverage
    https://finance.yahoo.com/news/lg-display-lpl-beats-q2-193841861.html

July 15, 2026

The 97% Signal: Why Millions of Diabetes Patients Are Ready to Ditch the Needle — and What One Company Is Doing About It -( $MODD $MDT $PODD $TNDM )

Modular Medical’s fresh research confirms what clinicians have long suspected: the “almost-pumper” market is enormous, underserved, and apparently very, very tired of injecting insulin in parking lots.

A Number Worth Repeating: 97%

In the often-cautious world of medical device commercialization, where product launches are hedged with asterisks and tempered with caveats, a survey result of 97% lands like a thunderclap.

Modular Medical, Inc. (NASDAQ: MODD), the San Diego-based developer of the Pivot™ tubeless insulin patch pump, announced on July 14, 2026, that it has completed an inaugural patient research initiative — and the headline finding is striking: 97% of surveyed injection users said they would consider pump therapy if it were easier to learn and delivered improved outcomes. Of the 100 individuals assessed — all multiple daily injection (MDI) users — virtually the entire cohort signaled openness to a simpler insulin delivery alternative. That is not a market trend. That is a market waiting to be unlocked.

The company also confirmed it will showcase the Pivot pump at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, from August 7–10, 2026 — one of the largest gatherings of diabetes care professionals in the country, drawing more than 3,000 clinicians annually.

The Injection Problem Nobody Talks About — Until Now

To appreciate what MODD’s research reveals, consider the daily reality of an insulin-dependent patient living on multiple injections. The Pivot research surfaced two additional data points that put texture around that 97% headline.

43% of participants had been hospitalized for severe glycemic events including hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS) — and among those, nearly half experienced such events two or more times per year. These are not near-misses. These are acute, life-threatening episodes that carry enormous costs to both patients and the healthcare system.

Meanwhile, 55% of survey participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while a full 31% faced this situation more than four times per week. To be blunt: more than half of MDI patients are regularly standing in restroom stalls, car seats, or restaurant booths, discreetly performing a medical procedure that no amount of clinical normalization fully dignifies. The practical burden of injection-based therapy — the privacy problem, the timing problem, the missed doses problem — is a feature of everyday life that large-cap incumbents have largely not addressed for this population.

Introducing the Pivot: Diabetes Care for the Rest of Us

The Pivot tubeless insulin patch pump is Modular Medical’s answer to that unmet need. Designed to provide continuous subcutaneous insulin infusion (CSII) with both basal and bolus insulin delivery over a three-day wear period, it is packaged in a wearable, tubeless format specifically engineered for ease of adoption. The Pivot received FDA 510(k) clearance in April 2026 and achieved U.S. commercial availability in June 2026 — a rapid progression from regulatory milestone to market entry. In July 2026, MODD filed a follow-on FDA submission covering software enhancements focused on patient customization and user-interface improvements.

Jeb Besser, CEO of Modular Medical, put it plainly: “The exceptionally high level of interest in simplified pump therapy validates our position that many people using multiple daily injections are ready to transition to an improved insulin delivery solution that reduces the burden without adding complexity. This huge market opportunity extends well beyond traditional pump users.”

The Target Market: 4.5 Million Underserved Patients and a $3 Billion Prize

The addressable opportunity for MODD is not theoretical. The company targets an estimated 4.5 million people in the United States living with Type 1 or insulin-requiring Type 2 diabetes who rely on both basal and mealtime injections — the group it calls “almost-pumpers.” Pump penetration statistics tell the story in cold arithmetic: fewer than 40% of U.S. Type 1 patients currently use a pump or automated insulin delivery system, while among intensive insulin-using Type 2 patients, that figure is just 5–6%.

The broader U.S. insulin pump market was valued at approximately $1.55 billion in 2024 and is projected to reach $2.58 billion by 2033. Insulet Corporation (NASDAQ: PODD), the dominant player in tubeless pumps via Omnipod, reported revenue of $761.7 million in Q1 2026 alone. Tandem Diabetes Care (NASDAQ: TNDM) and Medtronic (NYSE: MDT) round out the incumbents — all focused on technically proficient “superusers.” MODD is explicitly targeting the segment they left behind.

Thrivable Engagement: Turning Anecdotes Into Evidence

Savvy investors understand that the difference between a promising device company and a commercially successful one is often the quality of its patient intelligence infrastructure. Building on the initial 100-patient assessment, MODD has engaged Thrivable — the cardiometabolic patient intelligence partner — for an expanded research initiative. Thrivable will tap into its 130,000+ triple-verified patient panel to conduct in-depth engagement with 20 individuals living with diabetes and deliver a survey to an additional 300 insulin-using patients.

Thrivable, founded in 2019, is trusted by leading medtech, pharmaceutical, and healthcare organizations and has generated over 1,000,000 patient insights to date. Every member undergoes triple verification — ensuring data reflects genuine patient experience, not sample bias. The combination of 20 qualitative interviews and 300 quantitative survey responses represents a statistically credible foundation for commercial decision-making that will shape MODD’s go-to-market strategy, reimbursement narratives, and physician education programs.

ADCES 2026: A Critical Stage for the Pivot’s Debut

The ADCES Annual Conference — August 7–10, 2026, at the Greater Columbus Convention Center in Columbus, Ohio — is the premier event in diabetes care and education. For a company in active commercialization mode, exhibiting at ADCES is not merely a public relations exercise — it is a strategic deployment at the clinical decision point. DCESs are the frontline educators who counsel patients on insulin delivery options, coach pump transitions, and influence prescribing patterns.

Given that 97% of surveyed MDI patients expressed openness to pump therapy under the right conditions, the bottleneck is not patient demand — it is clinical awareness and recommendation. The ADCES conference creates a concentrated opportunity to close that gap, with over 3,000 diabetes care professionals gathered in one building.

The Investment Narrative: Small Cap, Large Market, Tight Thesis

MODD stock responded to the July 14 research announcement with a gain of approximately 9.77%, reflecting a notable positive market reaction and a valuation impact of roughly $2 million against a total market cap of approximately $23.71 million. That is a development-stage valuation being measured against a $3 billion addressable market — the math that attracts growth-oriented investors comfortable with early-stage medical device risk.

Modular Medical’s founder, Paul DiPerna, previously founded Tandem Diabetes Care (NASDAQ: TNDM) in 2005 and invented the t:slim insulin pump. The institutional DNA for insulin delivery engineering and commercial execution is embedded in MODD’s origin story. Key catalysts to monitor include: expanded Thrivable research findings, physician adoption metrics from the ADCES showcase, software enhancement FDA feedback, CE Mark progress targeting Q4 2026/Q1 2027, and early commercial revenue reporting.

Simplicity as a Competitive Moat

There is a certain irony in the medical device industry’s history with insulin pumps: the more sophisticated the technology became, the fewer people actually used it. Feature complexity, training requirements, cost, and physical cumbersomeness created an invisible ceiling on pump adoption that has persisted for over a decade.

Modular Medical’s thesis is that simplicity itself is a competitive moat — not a lesser offering, but a genuinely differentiated clinical strategy. The Pivot is not trying to out-feature the Omnipod 5 (NASDAQ: PODD) or Tandem’s Control-IQ system (NASDAQ: TNDM). It is trying to convert the 60%+ of Type 1 patients and 94% of intensive insulin-using Type 2 patients who remain on injections because no existing pump felt approachable enough to try. The 97% signal says the demand is there. Thrivable’s expanded research will tell MODD exactly how to reach it. And Columbus, Ohio in August will be where the clinical conversation begins in earnest.

Straight From The Founder

Payors Viewed The Pivot Tubeless Patch Pump As A Differentiated Offering

As part of its commercialization strategy, the Company announced on July 15 that it partnered with an independent organization specializing in the assessment of market viability, payor access, and commercialization strategies for therapeutic products. The firm specializes in supporting product launches, pricing assessments, reimbursement strategy, and go-to-market planning for life science companies. The objective of the engagement was to better understand payor receptivity, reimbursement considerations, and market positioning opportunities for the Pivot tubeless patch pump. The research indicated that payors viewed the Pivot tubeless patch pump as a differentiated offering within the insulin pump landscape. Respondents identified the system’s simple modular design, tubeless and reusable architecture, 300 international unit (IU) reservoir capacity, and intuitive one-button functionality as features that addressed unmet needs among insulin-dependent individuals seeking a less complex insulin delivery experience. These findings reinforce the Company’s belief that a significant opportunity exists to expand insulin pump adoption by reducing complexity and improving accessibility for a broader population of insulin-dependent people.

The assessment also explored potential reimbursement and coverage considerations. Feedback indicated that several payor organizations viewed Pivot favorably from a market access perspective, noting that its disposable component structure and anticipated contracting strategy align well with existing pharmacy benefit frameworks.

Beyond payor access considerations, the research also explored potential opportunities for strategic collaboration with large healthcare organizations. Respondents expressed strong interest in innovative partnership models that support broader patient access, evidence generation, and long-term adoption of simplified insulin delivery solutions.

Jeb Besser, CEO of Modular Medical concluded: “From the earliest stages of development, our goal has been to develop a practical and affordable insulin pumping solution that removes many of the barriers preventing insulin-dependent individuals from transitioning from multiple daily injections to pump therapy.The positive feedback from this market access assessment provides significant third-party validation of our commercialization strategy and reinforces Pivot’s differentiated value proposition with key payor stakeholders.”

The Sources

Here are the sources used across both articles, in numerical order:

  1. Modular Medical Research Completion – 97% Finding (Stock Titan)
    https://www.stocktitan.net/news/MODD/modular-medical-announces-completion-of-research-initiative-swq2e5bxceyu.html
  2. Modular Medical Survey Finds High Pump Therapy Interest (Street Insider)
    https://www.streetinsider.com/Corporate+News/Modular+Medical+survey+finds+high+pump+therapy+interest+among+injection+users/26765
  3. Modular Medical Receives FDA 510(k) Clearance for Pivot (Nasdaq)
    https://www.nasdaq.com/press-release/modular-medical-receives-fda-510k-clearance-pivot-tubeless-insulin-patch-pump-2026-04
  4. Modular Medical Announces Commercial Availability of Pivot (Yahoo Finance)
    https://finance.yahoo.com/healthcare/articles/modular-medical-announces-commercial-availability-121700614.html
  5. Modular Medical Announces FDA Submission of Pivot Enhancements (Nasdaq)
    https://www.nasdaq.com/press-release/modular-medical-announces-fda-submission-pivot-tubeless-insulin-patch-pump
  6. Modular Medical Delivers Insulin to First Patients on Pivot (Press Release)
    https://www.pressrelease.com/news/modular-medical-delivers-insulin-to-first-patients-on-pivot-tubeless-insulin
  7. Modular Medical Begins Shipping Pivot to Doctors (Investing.com)
    https://www.investing.com/news/company-news/modular-medical-begins-shipping-pivot-insulin-pump-to-doctors-93CH-4762691
  8. Modular Medical Research Initiative – AccessNewswire Full Release
    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-completion-of-research-initia
  9. Modular Medical Announces Licensing & Partnership with Nudge BG (AccessNewswire)
    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-licensing-and-partnership-agr
  10. Modular Medical Company Media Room (AccessNewswire)
    https://company-997241.suite.accessnewswire.com/browse/pr
  11. ADCES Annual Conference – Registration & Dates (ADCES)
    https://www.adcesmeeting.org/aaStatic.asp?SFP=RVNGQkNCTVVAMjUzOTNAUmVnaXN0cmF0aW9uIEluZm9ybWF0aW9u
  12. ADCES 2026 Conference Overview (ADCES.org)
    https://www.adces.org/
  13. ADCES Conferences Page
    https://www.adces.org/conferences/conferences
  14. Thrivable Pharma Solutions – Patient Insights Platform
    https://thrivable.app/solutions/pharma
  15. Thrivable Diabetes Research Panel
    https://thrivable.app/conditions/diabetes
  16. Thrivable G2 Reviews & Company Profile
    https://www.g2.com/products/thrivable/reviews
  17. United States Insulin Pump Market Outlook 2024–2033 (Yahoo Finance)
    https://finance.yahoo.com/news/united-states-insulin-pump-market-121300198.html
  18. Insulet Q1 2026 Earnings Results – PODD (Insulet Investor Relations)
    https://investor.insulet.com/news/news-details/2026/Insulet-Reports-First-Quarter-2026-Results/default.aspx
  19. Tandem Diabetes (TNDM) Research Report – Competitors Overview (StockStory)
    https://stockstory.org/us/stocks/nasdaq/tndm
  20. Meeting the Patch Pump Challenge – Market Penetration Analysis (LinkedIn/MedTech Strategist)
    https://www.linkedin.com/pulse/meeting-patch-pump-challenge-medtechstrategist
  21. Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump https://finance.yahoo.com/healthcare/articles/modular-medical-receives-research-demonstrating-120000361.html
Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

Copyright © 2026 Vista Partners, LLC. All rights reserved